Clinical Trial Update: Perioperative Immunotherapy for Resectable Limited-Stage SCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating perioperative immunotherapy for resectable limited-stage small cell lung cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Snippet

Sponsor: Fudan University | Conditions: Perioperative Immunotherapy, Limited Stage Lung Small Cell Carcinoma | Phase 2 | Status: RECRUITING